Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Prozac New Prescription Share Declines; Celexa, Effexor Make Gains

  • News

Executive Summary

Lilly Prozac's share of new prescriptions declined four percentage points year to date, according to IMS Health data.

You may also be interested in...



SmithKline Avandia Launch In EU Delayed By Negative CPMP Vote

SmithKline Beecham will work with European regulators over the next several months to persuade them to reverse a negative opinion from the Committee for Proprietary Medicinal Products regarding the approval of its antidiabetic Avandia (rosiglitazone).

SmithKline Avandia Launch In EU Delayed By Negative CPMP Vote

SmithKline Beecham will work with European regulators over the next several months to persuade them to reverse a negative opinion from the Committee for Proprietary Medicinal Products regarding the approval of its antidiabetic Avandia (rosiglitazone).

Lilly To Pay $4 Mil. To Delay Public Trial Of Prozac Patent Case

Lilly will pay $4 mil. to delay a public trial of its Prozac (fluoxetine) patent defense under a settlement announced Jan. 25.

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS035059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By